{"name":"Catalyst Pharmaceuticals","slug":"catalyst-pharma","ticker":"CPRX","exchange":"NASDAQ","domain":"catalystpharma.com","description":"Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.","hq":"Coral Gables, FL","founded":0,"employees":"182","ceo":"Patrick J. McEnany","sector":"Rare Neuromuscular Disease","stockPrice":25.66,"stockChange":0.67,"stockChangePercent":2.68,"marketCap":"$3.2B","metrics":{"revenue":119072803,"revenueGrowth":7.6,"grossMargin":83,"rdSpend":12709000,"netIncome":214326000,"cash":709171000,"dividendYield":0,"peRatio":15.3,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Firdapse patent cliff ($134.8M at risk)","drug":"Firdapse","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"The company reported net sales of $34.8 million for the fourth quarter and $134.8 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Catalyst Pharmaceuticals Announces Exclusive Distribution Agreement with Sandoz for Firdapse in the United States","summary":"The agreement grants Sandoz exclusive rights to distribute Firdapse in the US, expanding the product's reach and availability.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)","summary":"The FDA granted approval for Firdapse as a treatment for LEMS, marking a significant milestone for the company.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNZzV2dTBkeVZPVVR2RkJzM2RoVzh2M05hdWhOb0N3SDlCMWVvc2toZ2MycFFZbUp0SExxazBjSnNpZ1lfTHdrNjRNYXZacERKbjh5dEF1T0VuLXp4UEd3YlJTc2t2ZVhDWTVyNEdLREVoRGNfVElzSlAtb01lcDZ4dUh2eXJ2M0tKZWFEd0hQYXZhcGFPSWRlSzhhVUd1U2lfT3BiQnhLdkluRk95ZXBZWExDWERJYnk1YkNnZjRiTXZYTDQ?oc=5","date":"2026-03-18","type":"trial","source":"Stock Titan","summary":"Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026 - Stock Titan","headline":"Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOV21qV1AwLW1OY2gyR2NGckxrb1YwZGNrUUV4T2k0NjVwalNEVDJrVjBwWnBxZmh5aWxLeHlOdEdPWUhHbE5nU1FSUWRBV3dWVzBCSHVlTkFfVUp0a2hZaTRFZkhicWJYajNzb28zSE9xaDNNMTBvR09sSHBPWFpYSVlJNmNrclZzekloNDJmZm5sTVJyWjlzdGx3WW1iNk1OaXNNWlJfUnVLTlZBMm5yYmtGLW9ZbHhh?oc=5","date":"2026-03-18","type":"trial","source":"Stock Titan","summary":"Catalyst Pharmaceuticals (NASDAQ: CPRX) FIRDAPSE patent trial pushed to May 2026 - Stock Titan","headline":"Catalyst Pharmaceuticals (NASDAQ: CPRX) FIRDAPSE patent trial pushed to May 2026","sentiment":"neutral"},{"date":"2026-03-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOWmRiWEpDUU1uYUxHS09kSEZtTTVTVzYxTTlGeWNFbEFqYmRMTjB2SVI3TGtNT0xPemRDWW9YUU9wQTRnZmo0S2JzaGNJaHFIQW9HamxiVXFPQkU0U1dmWEIxSU9WWF9pSDhMMEZkOHFLSjZEYVh3X1FoXzdWN29mSVVQb3IwdTVZZ18yWDVYSE5sWmF0UnB2eVNjbE1oUDd0dHF5RDF3aFVmN3VJNkE4OVNRSTFfbVpiUWhhSUlwblk?oc=5","date":"2026-03-06","type":"trial","source":"Stock Titan","summary":"Real-world Duchenne data: how a novel steroid is used in care - Stock Titan","headline":"Real-world Duchenne data: how a novel steroid is used in care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPMUdneDhZc2x2VUU0eFQ4TmdNWGV1VXkxazQ5WEppNnhRaHFWck9CTU42Q2xxbUJGR0UwMHdSM2lkOE1YX2dMdzBBMThhc2JjbXlEZ0NPZUJ0SW5xU3ltRG0tNndfUHZVaXlmVTNiS3BaaG5CQkVvRnBOcGx5M0RGclR0OU1uN0JxVElTZVVVVjRPTE5aRGJDanlKUmUxSndpVEdxODdsV2d6Y1UtR09NLVFFRjBlSEZoXzNZSGVVUUR6U3ZqcXNmRnluTWtaQ00?oc=5","date":"2026-02-27","type":"earnings","source":"Investing.com UK","summary":"Oppenheimer reiterates Catalyst Pharmaceutical stock rating on revenue beat By Investing.com - Investing.com UK","headline":"Oppenheimer reiterates Catalyst Pharmaceutical stock rating on revenue beat By Investing.com","sentiment":"positive"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPMDBMbWJTUTNiM3Z5Yk03WklteTY1WDE5M3R0RmlabFVyX2NNRnFOOG5scnJTT1V5Q0E3THlkMzktMGdXdHFnbW1yVVM2TDZpUEF1M3N3d2toWkZiSW12WWR6ZTZjUVRwMFFrUjlpU29sTVZFS2ZLdFhzQXhIYmhLVEluajB2RWkwUnY0ZnVKUWJjSVRmVHFz?oc=5","date":"2026-02-18","type":"earnings","source":"Yahoo Finance","summary":"Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance","headline":"Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for","sentiment":"negative"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNdE1UbDZLcE55OVhoQjhQandsMkNTZDJ1VjlndEtlQlJPclZQVEtxN3BXOHd6MmVxa0VWZDRaQ2Q2c1BzQ0V2eUJ4ajR5M3RUbjk3X252cFFwS0lBVC1Xa3RQbC1NSEFackFfRUduUVRzZ0JxVG9zZHVMc0Jiby04Q2JnVlJ2OTB6N1FheHQtZVFhVTI1Q25vZWNvNkN4d3ZGMkxHUlEySQ?oc=5","date":"2025-10-29","type":"pipeline","source":"Seeking Alpha","summary":"Catalyst Pharmaceuticals: Cash Rich, But Running Out Of Catalysts (NASDAQ:CPRX) - Seeking Alpha","headline":"Catalyst Pharmaceuticals: Cash Rich, But Running Out Of Catalysts (NASDAQ:CPRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPOWdqNld6WXF1cVZjbThZX1BSRjRkdmpJNjVZbzVpUTJnUFVHeHpJclc1Q0NfbWg2aE9VcmlTRXM5X2VLQ3R4cUZYaUZMMjdkQkZYeW9JSjZNanNCeVBuZU1nWnNiY0VpdGRvZnVpVE94OVRYZ2lNdVJRTjgyajVmdXR3WnNTdXA0TGFxMA?oc=5","date":"2025-10-24","type":"pipeline","source":"Yahoo Finance","summary":"Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance","headline":"Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPRWlsbTNjLUIzdnZVbzdvQldkaWU4TEpEODRhbDlsYnpDeE9vbzJrQlpJa2ctZjF3WkRXdHFFWVBNN29jTy1SU0FTa0ZNUE1aWmw2dl85WDliVk9jY2VzR1ZxQjN4M29VTl92cks4eGQ5bFpFRUFBdTNsRkRMTzBpS0dUdm9TbzROYUVWUUQzZnY3b25fdW1hYi1ueDVJdUN4SlB4LVNoWnpwU3RXVHEyNnZfanVGX2xZaFNrOVpfY1c5a2dEblV1THN4ZHVHWU9VbE5sVzNaV0hHYTg0ODBndA?oc=5","date":"2025-10-01","type":"pipeline","source":"globenewswire.com","summary":"Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program - globenewswire.com","headline":"Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQdkhLS04yLWhmdGhYVW13NzdCZ3ZEUXVYOEFMMGd3SlpqYUt2bkVaVElueENuNGd0cno5OVc1UXVkNEt4cXk5VUFCeklGUXlZVHh2WGR5VzFsOGVNak5GU215ZGZYUHI1ekMzMlB1WjYwa0xYVDIxQUFpTG1ONk05VkVhbXpoVHBOTW04UA?oc=5","date":"2025-08-29","type":"pipeline","source":"Yahoo Finance","summary":"Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance","headline":"Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQSlI2N1FKendCUEl2T2E4dUtISTFVWnNkeHNzdVlnUFZzejFwU1hYNzZTdTEzQ0xXdGVaY2U2RnhEWS1laFlCcnd5NlpvWEJKOFpLWG9DLWJFSzNCeEVKXzUwd2pWNjRnRlFHMklTeW5xdXIzWXpfdWNOdlVjZTE0blpXbE5PZGt3MGhKeUJQNVFreVhSTjVZQTNjNmxIWFZnREM2NXp5b3NGZm13RWI3R2tFa2x3UQ?oc=5","date":"2025-05-31","type":"deal","source":"Seeking Alpha","summary":"Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma (NASDAQ:CPRX) - Seeking Alpha","headline":"Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma (NASDAQ:CPRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNbW0yR0dsZzhYWUVrVzcxTWkxOUFHcEczY0VDSGUyQzVIUUsyTmJHUkJCZURKYjJyYjRPRVQ1My04aDJ4NUlsR3JCY0pYRUtQRGt1OWtJYnVLYUh4b0h2ZnlWV2pIYTZodDgwNUhWZnJ2Y2NPY3lZNjZNSk1QSDU4eXZmOThmS3o1cGc?oc=5","date":"2025-03-27","type":"patent","source":"Investor's Business Daily","summary":"Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win - Investor's Business Daily","headline":"Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win - Investor's Business Daily","sentiment":"neutral"}],"patents":[{"drugName":"Firdapse","drugSlug":"amifampridine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":134800000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Pfizer","Sanofi"],"therapeuticFocus":["Rare Neuromuscular Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":119072803,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":119072803,"period":"2020-12-31"},{"value":102306337,"period":"2019-12-31"},{"value":500000,"period":"2018-12-31"},{"value":0,"period":"2017-12-31"},{"value":0,"period":"2017-09-30"},{"value":0,"period":"2017-06-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":12709000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":214326000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":709171000,"cashHistory":[],"totalAssets":1103979000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":182,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":25.66,"previousClose":24.99,"fiftyTwoWeekHigh":26.58,"fiftyTwoWeekLow":19.05,"fiftyTwoWeekRange":"19.05 - 26.58","fiftyDayAverage":24.1,"twoHundredDayAverage":22.23,"beta":0.66,"enterpriseValue":2345491968,"forwardPE":8.2,"priceToBook":3.29,"priceToSales":5.35,"enterpriseToRevenue":3.98,"enterpriseToEbitda":7.93,"pegRatio":0,"ebitda":295651008,"ebitdaMargin":50.2,"freeCashflow":171340256,"operatingCashflow":208670000,"totalDebt":2787000,"debtToEquity":0.3,"currentRatio":6.08,"returnOnAssets":16.5,"returnOnEquity":25.5,"analystRating":"","recommendationKey":"none","numberOfAnalysts":7,"targetMeanPrice":34,"targetHighPrice":36,"targetLowPrice":32,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":6.2,"institutionHeldPercent":89.3,"sharesOutstanding":122123884,"floatShares":114525336,"sharesShort":9703646,"shortRatio":7.79,"shortPercentOfFloat":8,"epsTrailing":1.68,"epsForward":3.12,"revenuePerShare":4.82,"bookValue":7.79,"officers":[{"age":78,"name":"Mr. Patrick J. McEnany","title":"Co-Founder & Non-Executive Chairman"},{"age":64,"name":"Mr. Richard John  Daly M.B.A.","title":"President, CEO & Director"},{"age":54,"name":"Mr. Michael W. Kalb CPA","title":"Executive VP, Treasurer & CFO"},{"age":63,"name":"Dr. Steven R. Miller Ph.D.","title":"Executive VP, COO & Chief Scientific Officer"},{"age":54,"name":"Mr. Jeffrey  Del Carmen","title":"Executive VP & Chief Commercial Officer"},{"age":49,"name":"Dr. Preethi  Sundaram Ph.D.","title":"Chief Strategy Officer"},{"age":null,"name":"Ms. Mary  Coleman","title":"VP & Head of Investor Relations"},{"age":61,"name":"Mr. Brian  Elsbernd J.D.","title":"Chief Compliance Officer & Chief Legal Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://catalystpharma.com","phone":"305 420 3200"}}